Brief Article
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Aug 28, 2013; 19(32): 5347-5356
Published online Aug 28, 2013. doi: 10.3748/wjg.v19.i32.5347
Efficacy profiles for different concentrations of Lactobacillus acidophilus in experimental colitis
Lin-Lin Chen, Yi-You Zou, Fang-Gen Lu, Fu-Jun Li, Guang-Hui Lian
Lin-Lin Chen, Yi-You Zou, Fu-Jun Li, Guang-Hui Lian, Department of Gastroenterology, Xiangya Hospital of Central South University, Changsha 410008, Hunan Province, China
Fang-Gen Lu, Department of Gastroenterology, Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China
Author contributions: Chen LL performed the experiments; Zou YY and Lu FG designed the study and revised the article for intellectual content; Li FJ and Lian GH analyzed the data, performed statistical analyses and revised the article for intellectual content.
Correspondence to: Lin-Lin Chen, MD, Department of Gastroenterology, Xiangya Hospital of Central South University, Kaifu District, No. 87 Xiangya Road, Changsha 410008, Hunan Province, China. chenlinlinmedical@gmail.com
Telephone: +86-731-84327332 Fax: +86-731-84327332
Received: March 13, 2013
Revised: June 3, 2013
Accepted: July 18, 2013
Published online: August 28, 2013
Processing time: 168 Days and 5.7 Hours
Abstract

AIM: To determine the efficacy profiles of different concentrations of Lactobacillus acidophilus (L. acidophilus) for treating colitis using an experimental murine model.

METHODS: Colitis was established in 64 BALB/c mice by adding 5% dextran sodium sulfate (DSS) to the drinking water and allowing ad libitum access for 7 d. The mice were then randomly divided into the following control and experimental model groups (n = 8 each; day 0): untreated model control; negative-treatment model control (administered gavage of 1 mL/10 g normal saline); experimental-treatment models C4-C8 (administered gavage of 104, 105, 106, 107, or 108 CFU/10 g L. acidophilus, respectively); positive-treatment model control (administration of the anti-inflammatory agent prednisone acetate at 45 μg/10 g). Eight mice given regular water (no DSS) and no subsequent treatments served as the normal control group. Body weight, fecal traits, and presence of fecal occult blood were assessed daily. All animals were sacrificed on post-treatment day 7 to measure colonic length, perform histological scoring, and quantify the major bacteria in the proximal and distal colon. Intergroup differences were determined by one-way ANOVA and post-hoc Student-Newman-Keuls comparison.

RESULTS: All treatments (L. acidophilus and prednisone acetate) protected against colitis-induced weight loss (P < 0.05 vs model and normal control groups). The extent of colitis-induced colonic shortening was significantly reduced by all treatments (prednisone acetate > C4 > C5 > C7 > C8 > C6; P < 0.05 vs untreated model group), and the C6 group showed colonic length similar to that of the normal control group (P > 0.05). The C6 group also had the lowest disease activity index scores among the model groups. The bacterial profiles in the proximal colon were similar between all of the experimental-treatment model groups (all P > 0.05). In contrast, the bacterial profile in the distal colon of the C6 group showed the distinctive features (P < 0.05 vs all other experimental-treatment model groups) of Lactobacillus sp. and Bifidobacterium sp. being the most abundant bacteria and Staphylococcus aureus being the least abundant bacteria.

CONCLUSION: The most therapeutically efficacious concentration of L. acidophilus (106 CFU/10 g) may exert its effects by modulating the bacterial profile in the distal colon.

Keywords: Lactobacillus acidophilus; Bifidobacterium; Colonic flora; Therapeutic dose; Experimental colitis; Efficacy profile

Core tip: Efficacies of the current treatments for ulcerative colitis (UC) are limited by procedure-related complications, poor patient compliance, and high relapse rates. Administration of supplemental probiotics represents a promising new therapy of UC. Since UC pathogenic sites mainly involve the rectum and colon and UC patients show differential composition profiles of intestinal bacteria, this study was designed to evaluate the therapeutic efficacies of various concentrations for the standard probiotic, Lactobacillus acidophilus, using a well-known murine model of experimental colitis to examine the changes in colitis symptoms and the corresponding effects on the bacterial flora in the distal and proximal colon.